Literature DB >> 2188930

VM-26 in colorectal carcinoma: a Southwest Oncology Group study.

N Oishi1, T R Fleming, L Laufman, J S Ungerleider, R B Natale, A B Einstein, D D Von Hoff, J S Macdonald.   

Abstract

In this multi-institutional phase II study, VM-26 or Teniposide was administered to forty-two patients with advanced colorectal cancer. Patients were initially treated at 60 mg/M2 daily for 5 days with dose adjustments depending on toxicity. One complete response and one partial response were observed lasting six and four months respectively. Leukopenia was severe in 40% of patients. No drug related deaths were seen. In this Southwest Oncology Group (SWOG) study, VM-26 appeared to have minimal benefit in advanced colorectal cancer.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2188930     DOI： 10.1007/bf00216931

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  6 in total

1.  Treatment of small cell bronchogenic carcinoma with VM-26.

Authors:  R L Woods; R M Fox; M H Tattersall
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

2.  Teniposide in metastatic renal and bladder cancer: a Southwest Oncology Group Study.

Authors:  N Oishi; J Berenberg; B A Blumenstein; K Johnson; S E Rivkin; R M Bukowski; R M O'Bryan; R L Stephens; J Quagliana; J H Saiers
Journal:  Cancer Treat Rep       Date:  1987-12

3.  Phase II trial of teniposide in previously treated and untreated patients with advanced colorectal carcinoma: an Illinois Cancer Council Trial.

Authors:  G Y Locker; V Lanzotti; J D Khandekar; D Sweet; J Shaw; J Bitran; L Gordon; S Krauss; C Johnson
Journal:  Cancer Treat Rep       Date:  1986-02

Review 4.  Teniposide: a review of 12 years of experience.

Authors:  P J O'Dwyer; M T Alonso; B Leyland-Jones; S Marsoni
Journal:  Cancer Treat Rep       Date:  1984-12

5.  Phase II study of VM-26 in adult malignancies.

Authors:  E Spremulli; J J Schulz; V J Speckhart; G L Wampler
Journal:  Cancer Treat Rep       Date:  1980-01

6.  Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.

Authors:  P Dombernowsky; N I Nissen; V Larsen
Journal:  Cancer Chemother Rep       Date:  1972-02
  6 in total
  1 in total

1.  VM-26 in gastric cancer. A Southwest Oncology Group study.

Authors:  J L Berenberg; C Tangen; J S Macdonald; B Barlogie; L R Laufman
Journal:  Invest New Drugs       Date:  1993-11       Impact factor: 3.850
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.